Valion Bio, Inc. Cash Flow Statement
VBIO|3 years of annual SEC 10-K data (FY2022-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Valion Bio, Inc. used $9M in operating cash flow and negative free cash flow of $9M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -10.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Net Income | -$8.2M | -$10.1M | -$8.5M |
| Depreciation & Amortization | $8.0K | $10.0K | $8.0K |
| Operating Cash Flow | -$8.5M | -$8.9M | -$5.6M |
| Capital Expenditures | $118.0K | $11.0K | $11.0K |
| Free Cash Flow | -$8.6M | -$8.9M | -$5.6M |
| FCF Margin | -733.8% | -485.3% | -447.3% |